NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages
NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target […]
More Stories
Stifel Nicolaus Forecasts Strong Price Appreciation for CyberArk Software (NASDAQ:CYBR) Stock
CyberArk Software (NASDAQ:CYBR – Get Free Report) had its price objective boosted by analysts at Stifel Nicolaus from $335.00 to...
Stifel Nicolaus Issues Positive Forecast for DigitalOcean (NYSE:DOCN) Stock Price
DigitalOcean (NYSE:DOCN – Get Free Report) had its target price raised by analysts at Stifel Nicolaus from $35.00 to $40.00...
News from the WHO: President Macron, WHO Director-General, and global health leaders inaugurate WHO Academy in Lyon https://ift.tt/IPbFCsE December 18, 2024 at 07:00AM
Published on December 18, 2024 at 07:00AM View on website
Acupuncture Proven Effective for Sciatica: Clinical Trial
By Jessica Lee Sciatica is a notoriously difficult condition to treat, with limited success from both conservative therapies and surgical...
Fastly (NYSE:FSLY) Shares Gap Up – Still a Buy?
Fastly, Inc. (NYSE:FSLY – Get Free Report)’s share price gapped up before the market opened on Wednesday . The stock...
Unum Group (NYSE:UNM) Given New $82.00 Price Target at Piper Sandler
Unum Group (NYSE:UNM – Get Free Report) had its target price boosted by analysts at Piper Sandler from $74.00 to...